Stammdaten
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Unternehmen & Branche
| Name | Alzamend Neuro, Inc. |
|---|---|
| Ticker | ALZN |
| CIK | 0001677077 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 3,4 Mio. USD |
| Beta | -0,05 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-01-31 | 10-Q | -2,198,991 | -0.58 | 4,041,833 | 2,184,505 | |
| 2025-10-31 | 10-Q | -1,000,758 | -0.30 | 5,091,684 | 4,374,196 | |
| 2025-07-31 | 10-Q | -2,702,684 | -1.28 | 6,326,751 | 5,343,440 | |
| 2025-04-30 | 10-K | -4,514,853 | -11.32 | 4,602,983 | 3,968,222 | |
| 2025-01-31 | 10-Q | -1,039,434 | -1.75 | 4,175,634 | 3,449,783 | |
| 2024-10-31 | 10-Q | -1,361,563 | -3.61 | 5,007,718 | 3,752,968 | |
| 2024-07-31 | 10-Q | -974,411 | -11.42 | 1,669,852 | -1,212,319 | |
| 2024-04-30 | 10-K | -9,947,746 | -132.33 | 631,588 | -2,594,185 | |
| 2024-01-31 | 10-Q | -2,662,418 | -3.77 | 782,636 | -4,263,821 | |
| 2023-10-31 | 10-Q | -2,906,033 | -4.43 | 983,597 | -2,682,493 | |
| 2023-07-31 | 10-Q | -3,527,766 | -5.38 | 2,628,005 | -112,883 | |
| 2023-04-30 | 10-K | -14,878,167 | -22.89 | 5,915,625 | 3,045,503 | |
| 2023-01-31 | 10-Q | -5,425,574 | -0.83 | 8,501,978 | 5,859,505 | |
| 2022-10-31 | 10-Q | -3,109,991 | -0.48 | 10,424,876 | 8,787,423 | |
| 2022-07-31 | 10-Q | -3,037,074 | -0.03 | 12,210,475 | 11,181,775 | |
| 2022-04-30 | 10-K | -12,362,059 | -0.14 | 14,516,443 | 13,351,511 | |
| 2022-01-31 | 10-Q | -2,572,865 | 12,429,116 | 11,962,139 | ||
| 2021-10-31 | 10-Q | -3,599,929 | 14,500,896 | 13,025,411 | ||
| 2021-07-31 | 10-Q | -2,319,867 | 16,817,651 | 15,344,256 | ||
| 2021-04-30 | 10-K | -5,046,567 | 2,912,590 | 2,012,947 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-14 | AULT MILTON C III | Director | Open Market Purchase | 108,388 | 1.00 | 108,897.42 | +125,8% | |
| 2025-12-23 | AULT MILTON C III | Director | Open Market Sale | -1,851 | 2.07 | -3,825.09 | -4,4% | |
| 2025-12-19 | Horne William B. | Director | Open Market Sale | -3,333 | 2.12 | -7,058.63 | -8,2% | |
| 2025-10-09 | AULT MILTON C III | Director | Open Market Sale | -20,397 | 2.32 | -47,390.39 | -54,7% | |
| 2025-10-08 | AULT MILTON C III | Director | Open Market Sale | -101,394 | 2.44 | -247,158.01 | -285,5% | |
| 2025-10-07 | AULT MILTON C III | Director | Open Market Sale | -57,379 | 2.49 | -142,954.04 | -165,1% | |
| 2025-10-06 | AULT MILTON C III | Director | Open Market Sale | -82,033 | 2.45 | -201,267.97 | -232,5% | |
| 2025-10-03 | AULT MILTON C III | Director | Open Market Sale | -65,903 | 2.44 | -160,888.99 | -185,8% | |
| 2025-10-02 | AULT MILTON C III | Director | Open Market Sale | -20,686 | 2.39 | -49,522.28 | -57,2% | |
| 2025-10-01 | AULT MILTON C III | Director | Open Market Sale | -36,777 | 2.35 | -86,378.14 | -99,8% | |
| 2025-09-30 | AULT MILTON C III | Director, 10% Owner | Open Market Sale | -3,566 | 2.33 | -8,320.90 | -9,6% | |
| 2025-09-29 | AULT MILTON C III | Director, 10% Owner | Open Market Sale | -38,324 | 2.31 | -88,490.12 | -102,2% | |
| 2025-09-26 | AULT MILTON C III | Director, 10% Owner | Open Market Sale | -37,738 | 2.31 | -87,344.60 | -100,9% | |
| 2025-09-25 | AULT MILTON C III | Director, 10% Owner | Open Market Sale | -14,628 | 2.31 | -33,828.71 | -39,1% | |
| 2025-09-24 | AULT MILTON C III | Director, 10% Owner | Open Market Sale | -39,140 | 2.31 | -90,374.26 | -104,4% | |
| 2025-09-23 | AULT MILTON C III | Director, 10% Owner | Open Market Sale | -43,238 | 2.38 | -102,720.52 | -118,6% | |
| 2025-09-19 | AULT MILTON C III | Director, 10% Owner | Open Market Sale | -77,009 | 2.35 | -180,855.64 | -208,9% | |
| 2025-09-18 | AULT MILTON C III | Director, 10% Owner | Open Market Sale | -20,870 | 2.47 | -51,492.55 | -59,5% | |
| 2025-09-17 | AULT MILTON C III | Director, 10% Owner | Open Market Sale | -2,121 | 2.45 | -5,203.87 | -6,0% | |
| 2025-07-31 | AULT MILTON C III | Director, 10% Owner | Open Market Sale | -100,000 | 2.22 | -221,550.00 | -255,9% | |
| 2025-07-30 | AULT MILTON C III | Director, 10% Owner | Open Market Sale | -29,449 | 2.51 | -73,981.78 | -85,4% | |
| 2025-07-28 | AULT MILTON C III | Director, 10% Owner | Open Market Sale | -8,311 | 2.68 | -22,314.20 | -25,8% | |
| 2025-07-25 | AULT MILTON C III | Director, 10% Owner | Open Market Sale | -36,532 | 2.90 | -105,855.12 | -122,3% | |
| 2025-07-24 | AULT MILTON C III | Director, 10% Owner | Open Market Sale | -9,621 | 2.93 | -28,236.67 | -32,6% | |
| 2025-07-23 | AULT MILTON C III | Director, 10% Owner | Open Market Sale | -59,516 | 2.95 | -175,584.10 | -202,8% | |
| 2025-05-12 | AULT MILTON C III | Director, 10% Owner | Open Market Sale | -1,213 | 5.06 | -6,138.27 | -7,1% | |
| 2025-05-12 | AULT MILTON C III | Director, 10% Owner | Open Market Sale | -11 | 5.28 | -58.08 | -0,1% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.